Browse > Article
http://dx.doi.org/10.5483/BMBRep.2017.50.11.129

Identification of specifically activated angiogenic molecules in HMGB-1-induced angiogenesis  

Kim, Won Kyu (Department of Pathology and Brain Korea 21 PLUS Projects for Medical Science, Yonsei University College of Medicine)
Kwon, Yujin (Department of Pathology and Brain Korea 21 PLUS Projects for Medical Science, Yonsei University College of Medicine)
Park, Minhee (Department of Pathology and Brain Korea 21 PLUS Projects for Medical Science, Yonsei University College of Medicine)
Yun, Seongju (Department of Pathology and Brain Korea 21 PLUS Projects for Medical Science, Yonsei University College of Medicine)
Kwon, Ja-Young (Departments of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine)
Kim, Hoguen (Department of Pathology and Brain Korea 21 PLUS Projects for Medical Science, Yonsei University College of Medicine)
Publication Information
BMB Reports / v.50, no.11, 2017 , pp. 590-595 More about this Journal
Abstract
High-mobility group box-1 (HMGB-1) is expressed in almost all cells, and its dysregulated expression correlates with inflammatory diseases, ischemia, and cancer. Some of these conditions accompany HMGB-1-mediated abnormal angiogenesis. Thus far, the mechanism of HMGB-1-induced angiogenesis remains largely unknown. In this study, we performed time-dependent DNA microarray analysis of endothelial cells (ECs) after HMGB-1 or VEGF treatment. The pathway analysis of each gene set upregulated by HMGB-1 or VEGF showed that most HMGB-1-induced angiogenic pathways were also activated by VEGF, although the activation time and gene sets belonging to the pathways differed. In addition, HMGB-1 upregulated some VEGFR signaling-related angiogenic factors including EGR1 and, importantly, novel angiogenic factors, such as ABL2, CEACAM1, KIT, and VIPR1, which are reported to independently promote angiogenesis under physiological and pathological conditions. Our findings suggest that HMGB-1 independently induces angiogenesis by activating HMGB-1-specific angiogenic factors and also functions as an accelerator for VEGF-mediated conventional angiogenesis.
Keywords
Angiogenesis; Endothelial cell; Gene expression profile; HMGB-1; VEGF;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Bonapace L, Coissieux MM, Wyckoff J et al (2014) Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. Nature 515, 130-133   DOI
2 Cai J, Yuan H, Wang Q et al (2015) HMGB1-Driven Inflammation and Intimal Hyperplasia After Arterial Injury Involves Cell-Specific Actions Mediated by TLR4. Arterioscler Thromb Vasc Biol 35, 2579-2593   DOI
3 Lotze MT and Tracey KJ (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat Rev Immunol 5, 331-342   DOI
4 Yusein-Myashkova S, Ugrinova I and Pasheva E (2016) Non-histone protein HMGB1 inhibits the repair of damaged DNA by cisplatin in NIH-3T3 murine fibroblasts. BMB Rep 49, 99-104   DOI
5 Tas SW, Maracle CX, Balogh E and Szekanecz Z (2016) Targeting of proangiogenic signalling pathways in chronic inflammation. Nat Rev Rheumatol 12, 111-122   DOI
6 Rampon C, Bouillot S, Climescu-Haulica A et al (2008) Protocadherin 12 deficiency alters morphogenesis and transcriptional profile of the placenta. Physiol Genomics 34, 193-204   DOI
7 Lv B, Wang H, Tang Y, Fan Z, Xiao X and Chen F (2009) High-mobility group box 1 protein induces tissue factor expression in vascular endothelial cells via activation of NF-kappaB and Egr-1. Thromb Haemost 102, 352-359   DOI
8 Liu L, Tsai JC and Aird WC (2000) Egr-1 gene is induced by the systemic administration of the vascular endothelial growth factor and the epidermal growth factor. Blood 96, 1772-1781
9 Kojima T, Chang JH and Azar DT (2007) Proangiogenic role of ephrinB1/EphB1 in basic fibroblast growth factor-induced corneal angiogenesis. Am J Pathol 170, 764-773   DOI
10 Song G, Li Y and Jiang G (2012) Role of VEGF/VEGFR in the pathogenesis of leukemias and as treatment targets (Review). Oncol Rep 28, 1935-1944   DOI
11 Gerstel D, Wegwitz F, Jannasch K et al (2011) CEACAM1 creates a pro-angiogenic tumor microenvironment that supports tumor vessel maturation. Oncogene 30, 4275-4288   DOI
12 Patruno R, Marech I, Zizzo N et al (2014) c-Kit expression, angiogenesis, and grading in canine mast cell tumour: a unique model to study c-Kit driven human malignancies. Biomed Res Int 2014, 730246
13 Valdehita A, Carmena MJ, Collado B, Prieto JC and Bajo AM (2007) Vasoactive intestinal peptide (VIP) increases vascular endothelial growth factor (VEGF) expression and secretion in human breast cancer cells. Regul Pept 144, 101-108   DOI
14 Tang B, Yong X, Xie R, Li QW and Yang SM (2014) Vasoactive intestinal peptide receptor-based imaging and treatment of tumors (Review). Int J Oncol 44, 1023-1031   DOI
15 Yang S, Xu L, Yang T and Wang F (2014) High-mobility group box-1 and its role in angiogenesis. J Leukoc Biol 95, 563-574   DOI
16 Hori O, Brett J, Slattery T et al (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of rage and amphoterin in the developing nervous system. J Biol Chem 270, 25752-25761   DOI
17 Park JS, Svetkauskaite D, He Q et al (2004) Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 279, 7370-7377   DOI
18 Ivanov S, Dragoi AM, Wang X et al (2007) A novel role for HMGB1 in TLR9-mediated inflammatory responses to CpG-DNA. Blood 110, 1970-1981   DOI
19 Biscetti F, Ghirlanda G and Flex A (2011) Therapeutic potential of high mobility group box-1 in ischemic injury and tissue regeneration. Curr Vasc Pharmacol 9, 677-681   DOI
20 Sims GP, Rowe DC, Rietdijk ST, Herbst R and Coyle AJ (2010) HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 28, 367-388   DOI
21 Jung B, Kang H, Lee W et al (2016) Anti-septic effects of dabrafenib on HMGB1-mediated inflammatory responses. BMB Rep 49, 214-219   DOI
22 Tang D, Kang R, Zeh HJ and Lotze MT (2010) High-mobility group box 1 and cancer. Biochim Biophys Acta 1799, 131-140   DOI
23 Maeda S, Hikiba Y, Shibata W et al (2007) Essential roles of high-mobility group box 1 in the development of murine colitis and colitis-associated cancer. Biochem Biophys Res Commun 360, 394-400   DOI
24 Sasahira T, Kirita T, Bhawal UK et al (2007) The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Arch 450, 287-295   DOI
25 Kim SW, Jin Y, Shin JH et al (2012) Glycyrrhizic acid affords robust neuroprotection in the postischemic brain via anti-inflammatory effect by inhibiting HMGB1 phosphorylation and secretion. Neurobiol Dis 46, 147-156   DOI
26 Ugele B and Lange F (2001) Isolation of endothelial cells from human placental microvessels: effect of different proteolytic enzymes on releasing endothelial cells from villous tissue. In Vitro Cell Dev Biol Anim 37, 408-413   DOI
27 Kacemi A, Challier JC, Galtier M and Olive G (1996) Culture of endothelial cells from human placental microvessels. Cell Tissue Res 283, 183-190   DOI
28 Kang R, Zhang Q, Zeh HJ, Lotze MT and Tang D (2013) HMGB1 in cancer: good, bad, or both? Clin Cancer Res 19, 4046-4057   DOI
29 Weidner N, Semple JP, Welch WR and Folkman J (1991) Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med 324, 1-8   DOI
30 van Beijnum JR, Dings RP, van der Linden E et al (2006) Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood 108, 2339-2348   DOI
31 Carmeliet P and Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307   DOI
32 Carmeliet P and Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407, 249-257   DOI
33 Jain RK, Duda DG, Willett CG et al (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 6, 327-338   DOI
34 Bergers G and Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8, 592-603   DOI